# YolTech Pharmaceuticals

a Shanghai in-vivo gene-editing company founded in 2021, building AAV-delivered base-editor platforms for cardiovascular and metabolic targets, backed by a more than 300 million yuan B round led by the AstraZeneca-CICC healthcare fund.

Source: https://en.bioecon.ru/companies/yoltech/
Updated: 2026-07-23

- Country: China

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $156 million cumulative funding as of May 2026 | https://endpoints.news/china-gene-editing-startup-yoltech-raises-70m-to-move-crispr-therapies-forward/, https://www.yoltx.com/news/press-release/112 |
| Production site | GMP-compliant manufacturing facility in Nanjing, China | https://www.yoltx.com/about/about-us, https://www.yoltx.com/news/press-release/76 |
| Capacity | 54,000 square feet after expansion | https://www.yoltx.com/news/press-release/76 |
| Regulatory approval | Multiple FDA and NMPA clinical trial clearances and designations for programs including YOLT-101, YOLT-201, YOLT-202, and YOLT-203 | https://crisprmedicinenews.com/news/clinical-update-yoltechs-base-editing-therapy-yolt-101-gains-chinese-ind-approval/, https://www.yoltx.com/about/about-us, https://www.yoltx.com/news/press-release/100, https://www.yoltx.com/news/press-release/110 |
| Revenue | Generated through R&D licensing agreements, including a $2 billion potential deal with Serapha and 1.035 billion yuan potential deal with Shenzhen Salubris Pharmaceuticals [medium confidence] | https://www.preqin.com/data/profile/asset/yoltech-therapeutics-co-ltd/469268 |

Independent sources: crisprmedicinenews.com, endpoints.news, preqin.com, yoltx.com

## Technologies

- [In-vivo gene therapy: AAV and lentiviral vectors](https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/)